Novartis files for Glivec approval

Less than three years after entering the clinic, Novartis (NVS; SWX:NOVN) filed an MAA and an NDA for its Glivec inhibitor of the altered Bcr-Abl kinase in patients with chronic myeloid leukemia (CML)...